Polpharma Group Restructures Leadership to Drive CEE Expansion

Polpharma Group has appointed Tamas Uri as the new General Director for the CEE region, aiming to strengthen its market position, accelerate strategic growth, and improve drug accessibility for patients.

Strengthening Regional Leadership

Polpharma Group is accelerating its development in Central and Eastern Europe, designating the region as a primary center for growth. To manage its increasing operational scale and strategic ambitions, the company has appointed Tamas Uri as the General Director for the CEE region.

Uri will be responsible for total regional management, including strategy execution, market integration, and efficiency improvements. His mandate focuses on scaling operations and fostering stronger international cooperation to ensure better access to medication.

A Strategic Asset for Transformation

Tamas Uri brings extensive experience in managing complex international structures to the group, including his previous role overseeing CEE and commercial operations at EGIS. His expertise in organizational transformation is expected to play a critical role in realizing Polpharma’s growth objectives.

Sebastian Szymanek, CEO of Polpharma Group, noted that this management shift enhances the company’s ability to act quickly and anticipate market needs. This new structure is designed to turn the group’s long-term strategy into concrete business results with greater consistency.

Operational Scale and Market Role

The company’s long-term strategy centers on scaling, innovation, and social responsibility within healthcare systems. By strengthening its regional management, Polpharma aims to solidify its status as a reliable partner and a leading pharmaceutical player in Europe.

About Polpharma

Founded in 1935, Polpharma is the leader of the Polish pharmaceutical market and a key manufacturer in the CEE region. It operates as a multiregional platform developing and producing prescription drugs, OTC products, and active pharmaceutical ingredients.

The company produces approximately 400 million packages of medication annually. Guided by its mission to help people live healthy lives, Polpharma invests in research, supports scientific development through the Polpharma Scientific Foundation, and adheres to strict ethical and environmental standards.